Cidara Therapeutics Presents New Promising Preclincal Data On Novel Dual-Acting Drug-Fc Conjugates At ESMO Immuno-Oncology Annual Congress
First in class, multi-specific CD73/PD-1 inhibitor DFC, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer at low doses CD73/PD-1 DFC demonstrated superior anti-tumor activity to